semaglutide and cardiovascular disease Evaluating the Benefits of Innovator 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of Current Evidence Study Finds Oral Semaglutide Vastly
Description
FDA updates rules on compounded GLP-1 drugs, impacting patients and providers
Up to 24.2% body weight reduction in 48 weeks (Phase 2, 12mg dose)
The BBC tests jabs, which claim to contain semaglutide - a prescription-only drug.
researchers are exploring how these drugs may affect more than appetite, blood sugar, and weight loss
GLP1, GLP2, GRPP
